↓ Skip to main content

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity

Overview of attention for article published in Frontiers in oncology, March 2022
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity
Published in
Frontiers in oncology, March 2022
DOI 10.3389/fonc.2022.821391
Pubmed ID
Authors

Wongeun Lee, Dong Kwon Kim, Chun-Bong Synn, Hee Kyu Lee, Sungho Park, Dong-Sik Jung, Yewon Choi, Jae Hwan Kim, Youngseon Byeon, Young Seob Kim, Seul Lee, Soyeon Lee, Yunjoo Joo, Eun Ji Lee, Mi Ran Yun, Seong Gu Heo, Wookyeom Yang, Ji Eun Jung, Eun Kyung Kim, Jooyeon Park, June Dong Park, Doo Jae Lee, Hyeon-Woo Kim, Sun Min Lim, Min Hee Hong, Beung-Chul Ahn, Jii Bum Lee, Kyoung-Ho Pyo

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 30%
Student > Bachelor 1 10%
Other 1 10%
Student > Ph. D. Student 1 10%
Student > Postgraduate 1 10%
Other 0 0%
Unknown 3 30%
Readers by discipline Count As %
Medicine and Dentistry 4 40%
Biochemistry, Genetics and Molecular Biology 3 30%
Unknown 3 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2022.
All research outputs
#20,580,732
of 26,166,431 outputs
Outputs from Frontiers in oncology
#9,608
of 22,913 outputs
Outputs of similar age
#322,284
of 452,477 outputs
Outputs of similar age from Frontiers in oncology
#618
of 1,519 outputs
Altmetric has tracked 26,166,431 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,477 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,519 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.